causal

Procedural irregularity causes rational hesitancy

When the FDA cuts procedural corners or approves on weak evidence—as in the controversial eteplirsen/Exondys approval for Duchenne muscular dystrophy over advisory-committee and division-director objections—it can produce rational hesitancy among informed purchasers, exemplified by insurers refusing to cover the drug because they don't know whether it works; this differs from psychologically driven vaccine hesitancy.

causalpending

Speaker

Daniel Carpenter

Evidence Quote

“These are informed purchasers. So, part of what happens when you have procedural irregularity or corners cut or bad evidence underlying approval decisions is, you get, in some cases, what might be rational hesitancy on the part of treatments.”

Source

Daniel Carpenter— Conversations with Tyler
Created: 6/13/2026, 3:23:23 AM

Your notes

Loading notes...